{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T14:58:56Z","timestamp":1787065136330,"version":"build-2736575974"},"reference-count":29,"publisher":"BMJ","issue":"6","license":[{"start":{"date-parts":[[2024,6,5]],"date-time":"2024-06-05T00:00:00Z","timestamp":1717545600000},"content-version":"unspecified","delay-in-days":4,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010877","name":"ViiV Healthcare","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100010877","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Asylum, Migration and Integration Funds","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]},{"name":"French Office for Immigration and Integration","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2023,12,14]]},"published-print":{"date-parts":[[2024,6]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Migrants from high HIV, hepatitis B virus (HBV) or hepatitis C virus (HCV) endemicity regions have a great burden of these infections and related diseases in the host countries. This study aimed to assess the predictive capacity of the Test Rapide d'Orientation Diagnostique (TROD) Screen questionnaire for HIV, HBV and HCV infections among migrants arriving in France.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>An observational and multicentre study was conducted among migrants. A self-questionnaire on demographic characteristics, personal medical history and sexual behaviours was completed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Setting<\/jats:title>\n                    <jats:p>The study was conducted in the centres of the French Office for Immigration and Integration (OFII).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Participants<\/jats:title>\n                    <jats:p>Convenience sampling was used to select and recruit adult migrants between January 2017 and March 2020.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Outcome measures<\/jats:title>\n                    <jats:p>Participants were tested for HIV, HBV and HCV with rapid tests. For each infection, the test performance was assessed using receiver operating characteristics curves, using area under the curve (AUC) as a measure of accuracy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 21\u2009133 regular migrants seen in OFII centres, 15\u2009343 were included in the study. The participants\u2019 mean age was 35.6 years (SD\u00b111.1). The prevalence (95% CI) of HBV, HCV and HIV was 2.0% (1.8% to 2.2%), 0.3% (0.2% to 0.4%) and 0.3% (0.2% to 0.4%), respectively. Based on the sensitivity\u2013specificity curve analysis, the cut-off points (95% CI) chosen for the risk score were: 2.5 (2.5 to 7.5) for HBV infection in men; 6.5 (0.5 to 6.5) for HBV infection in women; 9.5 (9.5 to 12.5) for HCV infection; and 10.5 (10.0 to 18.5) for HIV infection. Test performance was highest for HIV (AUC=82.15% (95% CI 74.54% to 87.99%)), followed by that for HBV in men (AUC=79.22%, (95% CI 76.18% to 82.26%)), for HBV in women (AUC=78.83 (95% CI 74.54% to 82.10%)) and that for HCV (AUC=75.95% (95% CI 68.58% to 83.32%)).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The TROD screen questionnaire showed good overall performance for predicting HIV, HBV and HCV infections among migrants in OFII centres. It could be used to optimise screening for these infections and to propose rapid screening tests to those who are at high risk.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT02959684\">NCT02959684<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2023-075315","type":"journal-article","created":{"date-parts":[[2024,6,5]],"date-time":"2024-06-05T21:40:50Z","timestamp":1717623650000},"page":"e075315","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":4,"title":["Development of a risk prediction score for screening for HBV, HCV and HIV among migrants in France: results from a multicentre observational study (STRADA study)"],"prefix":"10.1136","volume":"14","clinical-trial-number":[{"clinical-trial-number":"nct02959684","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Martin","family":"Duracinsky","sequence":"first","affiliation":[{"name":"Patient-Reported Outcomes Research (PROQOL), Health Economics Clinical Trial Unit (URC-ECO), Hotel-Dieu Hospital, AP- HP, Paris, France"},{"name":"ECEVE, UMR-S 1123, Paris Cit\u00e9 University, Inserm, Paris, France"},{"name":"Internal Medicine Unit, Le Kremlin Bic\u00eatre Hospital, Bic\u00eatre, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2554-6515","authenticated-orcid":false,"given":"Issifou","family":"Yaya","sequence":"additional","affiliation":[{"name":"Patient-Reported Outcomes Research (PROQOL), Health Economics Clinical Trial Unit (URC-ECO), Hotel-Dieu Hospital, AP- HP, Paris, France"},{"name":"ECEVE, UMR-S 1123, Paris Cit\u00e9 University, Inserm, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Yombo-Kokule","sequence":"additional","affiliation":[{"name":"Patient-Reported Outcomes Research (PROQOL), Health Economics Clinical Trial Unit (URC-ECO), Hotel-Dieu Hospital, AP- HP, Paris, France"},{"name":"ECEVE, UMR-S 1123, Paris Cit\u00e9 University, Inserm, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascal","family":"Bessonneau","sequence":"additional","affiliation":[{"name":"Patient-Reported Outcomes Research (PROQOL), Health Economics Clinical Trial Unit (URC-ECO), Hotel-Dieu Hospital, AP- HP, Paris, France"},{"name":"ECEVE, UMR-S 1123, Paris Cit\u00e9 University, Inserm, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fr\u00e9d\u00e9rique","family":"Thonon","sequence":"additional","affiliation":[{"name":"Patient-Reported Outcomes Research (PROQOL), Health Economics Clinical Trial Unit (URC-ECO), Hotel-Dieu Hospital, AP- HP, Paris, France"},{"name":"ECEVE, UMR-S 1123, Paris Cit\u00e9 University, Inserm, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivia","family":"Rousset-Torrente","sequence":"additional","affiliation":[{"name":"Patient-Reported Outcomes Research (PROQOL), Health Economics Clinical Trial Unit (URC-ECO), Hotel-Dieu Hospital, AP- HP, Paris, France"},{"name":"ECEVE, UMR-S 1123, Paris Cit\u00e9 University, Inserm, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7oise","family":"Roudot-Thoraval","sequence":"additional","affiliation":[{"name":"Departement de sant\u00e9 publique, H\u00f4pital Henri Mondor APHP, Universit\u00e9 Paris-Est, Cr\u00e9teil, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"France","family":"Lert","sequence":"additional","affiliation":[{"name":"Paris Fast Track City Initiative (FTCI) program, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Zucman","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Foch Hospital, Suresnes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Chassany","sequence":"additional","affiliation":[{"name":"Patient-Reported Outcomes Research (PROQOL), Health Economics Clinical Trial Unit (URC-ECO), Hotel-Dieu Hospital, AP- HP, Paris, France"},{"name":"ECEVE, UMR-S 1123, Paris Cit\u00e9 University, Inserm, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2024,6,5]]},"reference":[{"key":"2025120618460238000_14.6.e075315.1","unstructured":"World Health Organization (WHO) . Hepatitis B, Available: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/hepatitis-b"},{"key":"2025120618460238000_14.6.e075315.2","unstructured":"World Health Organization (WHO) . Global hepatitis report 2017. Geneva: WHO. 2017."},{"key":"2025120618460238000_14.6.e075315.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2011.12.116"},{"key":"2025120618460238000_14.6.e075315.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2015.04.026"},{"key":"2025120618460238000_14.6.e075315.5","article-title":"Migration and health: exploring the role of migrant status through register-based studies","volume":"62","author":"N\u00f8rredam","year":"2015","journal-title":"Dan Med J"},{"key":"2025120618460238000_14.6.e075315.6","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0044611","article-title":"Seroprevalence of chronic hepatitis B virus infection and prior immunity in immigrants and refugees: a systematic review and meta-analysis","volume":"7","author":"Rossi","year":"2012","journal-title":"PLoS One"},{"key":"2025120618460238000_14.6.e075315.7","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0141715","article-title":"The Seroprevalence of hepatitis C antibodies in immigrants and refugees from intermediate and high Endemic countries: A systematic review and meta-analysis","volume":"10","author":"Greenaway","year":"2015","journal-title":"PLoS ONE"},{"key":"2025120618460238000_14.6.e075315.8","unstructured":"Delmas G , Ndeikoundam Ngangro N , Brouard C , et al . n.d. Surveillance Surcegidd: D\u00e9pistage et diagnostic Du VIH, des H\u00e9patites B et C et des IST Bact\u00e9riennes en Cegidd en 2020. Bull Epid\u00e9miol Hebd;2021:401\u201312."},{"key":"2025120618460238000_14.6.e075315.9","unstructured":"Saboni L , Brouard C , Gautier A , et al . Pr\u00e9valence des H\u00e9patites Chroniques C et B, et Ant\u00e9c\u00e9dents de D\u00e9pistage en population G\u00e9n\u00e9rale en 2016: contribution \u00c0 une Nouvelle Strat\u00e9gie de D\u00e9pistage, Barom\u00e8tre de Sant\u00e9 Publique France-Barotest. Bull Epid\u00e9miol Hebd 2019:469\u201377."},{"key":"2025120618460238000_14.6.e075315.10","unstructured":"Larsen C , Limousi F , Rahib D , et al . Infections VIH et VHB Parmi LES Afro-Carib\u00e9ens D\u2019\u00cele-de-France: des Pr\u00e9valences \u00c9lev\u00e9es et des D\u00e9pistages Insuffisants. Bull Epid\u00e9miol Hebd 2017:609\u201316."},{"key":"2025120618460238000_14.6.e075315.11","unstructured":"Pioche C , L\u00e9on L , Vaux S , et al . D\u00e9pistage des H\u00e9patites B et C en France en 2016, Nouvelle \u00c9dition de L\u2019Enqu\u00eate Labohep. Bull \u00c9pid\u00e9miologique Hebd 2018:188\u201395."},{"key":"2025120618460238000_14.6.e075315.12","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2458-10-512","article-title":"Awareness, knowledge and self-reported test rates regarding hepatitis B in Turkish-Dutch: a survey","volume":"10","author":"van der Veen","year":"2010","journal-title":"BMC Public Health"},{"key":"2025120618460238000_14.6.e075315.13","first-page":"1","article-title":"Recommendations for identification and public health management of persons with chronic hepatitis B virus infection","volume":"57","author":"Weinbaum","year":"2008","journal-title":"MMWR Recomm Rep Morb Mortal Wkly Rep Recomm Rep"},{"key":"2025120618460238000_14.6.e075315.14","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0235260","article-title":"Good acceptability of HIV, HBV, and HCV screening during immigration medical check-up amongst migrants in France in the STRADA study","volume":"15","author":"Duracinsky","year":"2020","journal-title":"PLoS One"},{"key":"2025120618460238000_14.6.e075315.15","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.cmi.2016.01.009","article-title":"Prospective assessment of rapid diagnostic tests for the detection of antibodies to hepatitis C virus, a tool for improving access to care","volume":"22","author":"Chevaliez","year":"2016","journal-title":"Clin Microbiol Infect"},{"key":"2025120618460238000_14.6.e075315.16","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.jcv.2017.09.012","article-title":"Performance of rapid diagnostic tests for the detection of anti-HBs in various patient populations","volume":"96","author":"Poiteau","year":"2017","journal-title":"J Clin Virol"},{"key":"2025120618460238000_14.6.e075315.17","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.diagmicrobio.2018.10.002","article-title":"Field evaluation of a dual rapid human immunodeficiency virus and Treponemal Syphilis rapid test in community-based clinics in Los Angeles and New York","volume":"93","author":"Stafylis","year":"2019","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2025120618460238000_14.6.e075315.18","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2008.01.034"},{"key":"2025120618460238000_14.6.e075315.19","doi-asserted-by":"publisher","DOI":"10.1002\/sim.6994"},{"key":"2025120618460238000_14.6.e075315.20","first-page":"403","article-title":"Occult hepatitis B infection among blood donors from Yaound\u00e9, Cameroon","volume":"17","author":"Fopa","year":"2019","journal-title":"Blood Transfus"},{"key":"2025120618460238000_14.6.e075315.21","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0258932","article-title":"Hepatitis B virus (HBV), hepatitis C virus (HCV) and human immunodeficiency virus (HIV) infections among Undocumented migrants and uninsured legal residents in the Netherlands: A cross-sectional study, 2018-2019","volume":"16","author":"Klok","year":"2021","journal-title":"PLoS One"},{"key":"2025120618460238000_14.6.e075315.22","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v21.i42.11941"},{"key":"2025120618460238000_14.6.e075315.23","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2334-14-7","article-title":"Efficacy and effectiveness of infant vaccination against chronic hepatitis B in the Gambia hepatitis intervention study (1986\u201390) and in the nationwide Immunisation program","volume":"14","author":"Peto","year":"2014","journal-title":"BMC Infect Dis"},{"key":"2025120618460238000_14.6.e075315.24","doi-asserted-by":"crossref","first-page":"74","DOI":"10.4254\/wjh.v4.i3.74","article-title":"Epidemiology and prevention in developing countries","volume":"4","author":"Franco","year":"2012","journal-title":"WJH"},{"key":"2025120618460238000_14.6.e075315.25","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)60220-8"},{"key":"2025120618460238000_14.6.e075315.26","doi-asserted-by":"publisher","DOI":"10.1093\/labmed\/lmw003"},{"key":"2025120618460238000_14.6.e075315.27","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0241086","article-title":"Sero-prevalence of transfusion transmittable infections: HIV, hepatitis B, C and Treponema Pallidum and associated factors among blood donors in Ethiopia: A retrospective study","volume":"15","author":"Abdella","year":"2020","journal-title":"PLoS One"},{"key":"2025120618460238000_14.6.e075315.28","doi-asserted-by":"crossref","DOI":"10.7448\/IAS.19.1.21270","article-title":"High prevalence of HIV, Chlamydia and Gonorrhoea among men who have sex with men and Transgender women attending trusted community centres in Abuja and Lagos, Nigeria","volume":"19","author":"Keshinro","year":"2016","journal-title":"J Int AIDS Soc"},{"key":"2025120618460238000_14.6.e075315.29","doi-asserted-by":"publisher","DOI":"10.1136\/sextrans-2020-054755"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2023-075315","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,7]],"date-time":"2025-12-07T02:46:10Z","timestamp":1765075570000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2023-075315"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":29,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,6,5]]},"published-print":{"date-parts":[[2024,6]]}},"alternative-id":["10.1136\/bmjopen-2023-075315"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2023-075315","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6]]}}}